Abstract:Vinith Yathindranath, 1, 2 Nura Safa, 1, 2 Mateusz Marek Tomczyk, 1, 3 Vernon Dolinsky, 1, 3 Donald W Miller 1, 2 1 Department of Pharmacology and Therapeutics, University of Manitoba, Winnipeg, MB, Canada; 2 PrairieNeuro Research Centre, Health Science Centre, Winnipeg, MB, Canada; 3 Children's Hospital Research Institute Manitoba, Health Science Centre, Winnipeg, MB, Canada Correspondence: Donald W Miller, Tel +1 204 789 3278, Email Purpose: The global pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lingering threat to public health has fueled the search for effective therapeutics to treat SARS-CoV-2. This study aimed to develop lipid nanoparticle (LNP) inhibitors of SARS-CoV-2 entry to reduce viral infection in the nose and upper airway. Methods: Two types of LNP formulations were prepared following a microfluidic mixing method. The LNP-Trap consisted of DOPC, DSPC, cholesterol, and DSPE-PEG-COOH modified with various spike protein binding ligands, including ACE2 peptide, recombinant human ACE2 (rhACE2) or monoclonal antibody to spike protein (mAb). The LNP-Trim consisted of ionizing cationic DLin-MC3-DMA, DSPC, cholesterol, and DMG-PEG lipids encapsulating si ACE2 or si TMPRSS2 . Both formulations were assayed for biocompatibility and cell uptake in airway epithelial cells (Calu-3). Functional assessment of activity was performed using SARS-CoV-2 spike protein binding assays (LNP-Trap), host receptor knockdown (LNP-Trim), and SARS-CoV-2 pseudovirus neutralization assay (LNP-Trap and LNP-Trim). Localization and tissue distribution of fluorescently labeled LNP formulations were assessed in mice following intranasal administration. Results: Both LNP formulations were biocompatible based on cell impedance and MTT cytotoxicity studies in Calu-3 cells at concentrations as high as 1 mg/mL. LNP-Trap formulations were able to bind spike protein and inhibit pseudovirus infection by 90% in Calu-3 cells. LNP-Trim formulations reduced ACE2 and TMPRSS2 at the mRNA (70% reduction) and protein level (50% reduction). The suppression of host targets in Calu-3 cells treated with LNP-Trim resulted in over 90% inhibition of pseudovirus infection. In vivo studies demonstrated substantial retention of LNP-Trap and LNP-Trim in the nasal cavity following nasal administration with minimal systemic exposure. Conclusion: Both LNP-Trap and LNP-Trim formulations were able to safely and effectively inhibit SARS-CoV-2 pseudoviral infection in airway epithelial cells. These studies provide proof-of-principle for a localized treatment approach for SARS-CoV-2 in the upper airway. Keywords: lipid nanoparticles, SARS-CoV-2, antiviral, gene knockdown, intranasal drug delivery Graphical The emergence of a novel SARS-coronavirus-2 (SARS-CoV-2) and the resulting COVID-19 pandemic has had crippling effects on public health and the global economy. Statistics from the World Health Organization (WHO) reported over 758 million confirmed cases of COVID-19 and over 6.8 million related deaths. 1 The COVID-19 and earlier SARS (2002) and Middle East respiratory syndrome (MERS; 2012) outbreaks were caused by closely related coronaviruses (CoV). 2 These viruses use spike proteins to bind and gain entry to specific host cell receptors during infection. While the development of effective vaccines for SARS-CoV-2 has been critical in slowing the spread and limiting mortality, reliance on vaccination alone is not sufficient as there remain sizeable portions of the population that are not fully vaccinated. Furthermore, there remains the possibility for variants of concern (VOC) to emerge that have reduced response to vaccines and present an even greater risk of infection and morbidity. 3 Given that SARS-CoV-2 will likely remain a concern going forward in the foreseeable future, there is a need to continue identification and development of additional treatment options for this virus and any emerging variants of interest that may appear. Initially, efforts at identifying antiviral agents effective against SARS-CoV-2 focused on repurposing existing chemical libraries of approved drugs. 4,5 These efforts identified several potential therapeutics and resulted in some "hits" that have been of use, such as dexamethasone for ICU and ventilated patients, Paxlovid (orally active), and Remdesivir (iv infusion) antivirals for use in infected patients at risk of morbidity or death from severe infection. 6–8 Administration of convalescent plasma from recovered COVID-19 patients was also reported to prevent hospitalizations in a clinical tr -Abstract Truncated-

Nanotraps for the Containment and Clearance of SARS-CoV-2

Cellular Nanoparticles Treat Coronavirus Infection in Vivo

Protein Nanoparticles for Targeted SARS‐CoV‐2 Trapping and Neutralization

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

Lysosomal “TRAP”: a Neotype Modality for Clearance of Viruses and Variants

Membrane Nanoparticles Derived from ACE2-Rich Cells Block SARS-CoV-2 Infection.

A Multifunctional Neutralizing Antibody‐Conjugated Nanoparticle Inhibits and Inactivates SARS‐CoV‐2

A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination

Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2

Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS‐CoV‐2 Pseudovirus Entry into Lung ACE2+ Cells

Nanobody-Functionalized Cellulose for Capturing and Containing SARS-CoV-2

Inhalable nanocatchers for SARS-CoV-2 inhibition

Lipid Nanoparticle-Based Inhibitors for SARS-CoV-2 Host Cell Infection

A Potent Neutralizing Nanobody Targeting the Spike Receptor-Binding Domain of SARS-CoV-2 and the Structural Basis of Its Intimate Binding

Nanobody engineering for SARS-CoV-2 neutralization and detection

Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS‐CoV‐2 Pseudovirus Entry into Lung ACE2+ Cells (Adv. Mater. 15/2024)

Nanobody against SARS-CoV-2 non-structural protein Nsp9 inhibits viral replication in human airway epithelia

AI‐Driven Design System for Fabrication of Inhalable Nanocatchers for Virus Capture and Neutralization

Cell-Mimicking Nanodecoys Protect Lung Cells by Neutralization of SARS-CoV-2 Spike Proteins

Engineered Intranasal Virus Trap Provides Effective Protection Against SARS‐CoV‐2 Infection in Hamsters

Biomimetic Nanotechnology for SARS-CoV-2 Treatment